Article
Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism.
Neurology - 14 Aug 2001
Graf W D, Unis A S, Yates C M, Sulzbacher S, Dinulos M B, Jack R M, Dugaw K A, Paddock M N, Parson W W
Abstract excerpt
OBJECTIVE: To investigate catecholamine phenotypes and the effects of a tyrosine hydroxylase inhibitor in individuals with the 22q11.2 deletion syndrome and low-activity catechol-O-methyltransferase (COMT). BACKGROUND: Many persons with the 22q11.2 deletion syndrome suffer severe disability from a characteristic ultrarapid-cycling bipolar disorder and associated "affective storms." One etiologic hypothesis for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
